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Purpose of the study
The TAIL study determined plasma concentrations of lopi-
navir/ritonavir (LPV/RTV) over 72 hours following cessa-
tion of LPV/RTV (400/100 mg twice daily) in healthy
volunteers. There was a rapid decline in LPV concentra-
tions as RTV diminished over time [1]. Here we have
determined a model to quantify the changes in LPV appar-
ent oral clearance (CL/F) in relation to RTV concentra-
tions.
Methods
Plasma LPV and RTV concentrations were determined by
HPLC-MS/MS. Initially, non-linear mixed effects model-
ling was applied (NONMEM vs. VI) to LPV and RTV data
separately using first-order conditional estimation with
interaction. Secondly, individual predicted RTV pharma-
cokinetic (PK) parameters were fed into a model to deter-
mine LPV PK parameters assuming competitive inhibition
by RTV. Model fit was assessed by statistical and graphical
methods. A decrease in minimal objective function value
(OFV) of 3.84 points corresponded to a statistically signif-
icant difference between hierarchical models.
Summary of results
Sixteen healthy volunteers (six female) were included. A
one-compartment model with zero-order absorption was
used to generate RTV parameters. Initially, a one-compart-
ment first-order absorption model was used for LPV in the
combined model; however, under-prediction of concen-
trations in the early absorption phase and over-prediction
in parts of the elimination phase occurred. A one-com-
partment zero-order absorption model for LPV improved
the fit (OFV -157.934) and was parameterised by LPV
clearance in the absence of inhibitor (CL0), apparent vol-
ume of distribution (V/F), CL/F and RTV inhibition con-
stant (Ki) with inter-individual variability (IIV) included
on CL0 and V/F. Residual error was described by a com-
bined additive-proportional model. A first-pass model
produced similar estimations. Parameter estimates and
time-dependent changes in LPV CL/F are shown (Table 1;
Figure 1, respectively). Larger changes in LPV CL/F were
observed from approximately 10 hours post-dose com-
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Table 1: Parameter estimates and standard errors.
Parameter Estimate Standard Error
CL0 (L/h) 53.2 8.09
Ki (mg/L) 0.0442 0.0102
V/F (L) 124 8.90
IIV CL0 (%) 16.2 9.69
IIV V/F 12.8 8.67
Residual error – proportional (%) 28.8 12.6
Residual error – additive (mg/L) 0.0117 0.00849Page 1 of 2
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pared to 0.5–8 hours post-dose (3.04–63.83 vs.
0.40–12.99 L/h).
Conclusion
A model assuming competitive inhibition of LPV by RTV
combined with zero-order kinetics best described the
time-dependent changes in LPV CL/F following drug ces-
sation. Given the complexity of the LPV-RTV interaction,
potentially more complex models should be explored.
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